NANO. 5 new patents granted in 2018. Provisional..............
Why do you not inform the market about this Mr Bravo............................?
Grant 2018
2018-07-27 CN105451781B - Chinese / Title : A method for regulated expression of the antigen
2018-05-30 JP6335284B2 - Japan / Title : Method for upregulate antigen expression
2018-04-16 DK3003402T3 - Danmark / Title : Combination therapy comprising the rituximab and the radiolabeled monoclonal antibody, HH1
2018-04-10 ES2662964T3 - Spain / Title : Combination therapy comprising the monoclonal antibody rituximab and radiolabelled HH1
2018-01-17 EP3003402B1 - EU patent / Title : Combination therapy comprising rituximab and the radiolabeled hh1 monoclonal antibody
Patent aplication US201414890737 is abandonment 10.07.2018. Title : Method for regulated expression of the antigen
Population
China 1,415,045,928
Japan 127,185,332
E.U. 509,697,104
U.S.A. 326,766,748
-----------------------------------------------------------------------
When this patent application is granted and Betalutin is approved.......................... Rituximab disappears ?
TREATMENT OF NON-HODGKIN LYMPHOMA USING LILOTOMAB AND 177LU-LILOTOMAB SATETRAXETAN
http://www.sumobrain.com/patents/wipo/Treatment-non-hodgkin-lymphoma-using/WO2018050851A1.pdf
Publication date : 22 March 2018 WO 2018/050851 - WIPO
-------------------------------------------------------------------------
The ratio doubled for patients receiving 40 mg lilotomab and doubled again for the patients given 100 mg/m2 BSA of lilotomab, indicating that the higher pre-dosing level can optimize the therapeutic effect.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5953993/
Costa ................We are entering a very competetive market, and we are making a lot of companies worried"..........BRAVO
Grant 2018
2018-07-27 CN105451781B - Chinese / Title : A method for regulated expression of the antigen
2018-05-30 JP6335284B2 - Japan / Title : Method for upregulate antigen expression
2018-04-16 DK3003402T3 - Danmark / Title : Combination therapy comprising the rituximab and the radiolabeled monoclonal antibody, HH1
2018-04-10 ES2662964T3 - Spain / Title : Combination therapy comprising the monoclonal antibody rituximab and radiolabelled HH1
2018-01-17 EP3003402B1 - EU patent / Title : Combination therapy comprising rituximab and the radiolabeled hh1 monoclonal antibody
Patent aplication US201414890737 is abandonment 10.07.2018. Title : Method for regulated expression of the antigen
Population
China 1,415,045,928
Japan 127,185,332
E.U. 509,697,104
U.S.A. 326,766,748
-----------------------------------------------------------------------
When this patent application is granted and Betalutin is approved.......................... Rituximab disappears ?
TREATMENT OF NON-HODGKIN LYMPHOMA USING LILOTOMAB AND 177LU-LILOTOMAB SATETRAXETAN
http://www.sumobrain.com/patents/wipo/Treatment-non-hodgkin-lymphoma-using/WO2018050851A1.pdf
Publication date : 22 March 2018 WO 2018/050851 - WIPO
-------------------------------------------------------------------------
The ratio doubled for patients receiving 40 mg lilotomab and doubled again for the patients given 100 mg/m2 BSA of lilotomab, indicating that the higher pre-dosing level can optimize the therapeutic effect.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5953993/
Costa ................We are entering a very competetive market, and we are making a lot of companies worried"..........BRAVO
Redigert 21.01.2021 kl 01:58
Du må logge inn for å svare
Hugoil
04.09.2018 kl 15:01
1885
Dette er vel uttak av patent i de enkelte land, etter at sentralpatentet/EPO er gitt.
Redigert 21.01.2021 kl 01:58
Du må logge inn for å svare
Flottesen
04.09.2018 kl 20:49
1671
Hvorfor skulle rituximab forsvinne? Betalutin kommer jo aldri til å fortrenge rituximab.
Redigert 21.01.2021 kl 01:58
Du må logge inn for å svare
Frontmasta
04.09.2018 kl 21:28
1574
From Internett :
However, too much cold anti-CD20 antibody over a long time can result in blocking of the CD20 antigen on tumour cells and thus reduce the effect of anti-CD20 RIT. Both clinical and non-clinical studies have shown that in some circumstances quite low rituximab concentrations in the blood can reduce tumour cell targeting and thus impair the clinical efficacy of CD20-directed RIT. A solution to this problem might be to omit cold rituximab from the last cycles of therapy before RIT. Alternatively; one could choose to target another B-cell surface antigen such as CD37.
------------------------------------------------------------
The present inventors have to their surprise found when doing experiments with low dose rate beta emitting 177Lu-labeled HH1 antibody (also named 177Lu-tetulomab or Betalutin) against the B-cell associated antigen CD37, that cells treated with this would up-regulate the expression of both CD37 and CD20.
The management knows more facts today ....................BRAVO !
However, too much cold anti-CD20 antibody over a long time can result in blocking of the CD20 antigen on tumour cells and thus reduce the effect of anti-CD20 RIT. Both clinical and non-clinical studies have shown that in some circumstances quite low rituximab concentrations in the blood can reduce tumour cell targeting and thus impair the clinical efficacy of CD20-directed RIT. A solution to this problem might be to omit cold rituximab from the last cycles of therapy before RIT. Alternatively; one could choose to target another B-cell surface antigen such as CD37.
------------------------------------------------------------
The present inventors have to their surprise found when doing experiments with low dose rate beta emitting 177Lu-labeled HH1 antibody (also named 177Lu-tetulomab or Betalutin) against the B-cell associated antigen CD37, that cells treated with this would up-regulate the expression of both CD37 and CD20.
The management knows more facts today ....................BRAVO !
Redigert 21.01.2021 kl 01:58
Du må logge inn for å svare